{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:31:21Z","timestamp":1777984281780,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04807-2","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:54:43Z","timestamp":1770782083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mesangial sclerosing glomerulopathy following luspatercept treatment \u2013 a case report"],"prefix":"10.1186","volume":"27","author":[{"given":"Stanislas","family":"Bataille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Torrents","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Javaugue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Giaime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Castoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie-Jade","family":"Poir\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Burtey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"2","key":"4807_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","volume":"382","author":"P Fenaux","year":"2020","unstructured":"Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. 2020, 9 janv 382(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"4807_CR2","first-page":"11","volume":"13","author":"S Delanghe","year":"2022","unstructured":"Delanghe S, Nguyen TQ, Mazure D, Dendooven A, Speeckaert MM. Immune complex glomerulonephritis in a patient with myelodysplastic syndrome with ring sideroblasts treated with luspatercept. Diagn Basel Switz. 2022, 21 d\u00e9c 13(1):11.","journal-title":"Diagn Basel Switz"},{"issue":"2","key":"4807_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International working group for the prognosis of MDS. Blood. 2020, 9 juill 136(2):157\u201370.","journal-title":"Blood"},{"issue":"5","key":"4807_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1046\/j.1523-1755.2002.00628.x","volume":"62","author":"F Bridoux","year":"2002","unstructured":"Bridoux F, Hugue V, Coldefy O, Goujon JM, Bauwens M, Sechet A, et al. Fibrillary glomerulonephritis and immunotactoid (microtubular) glomerulopathy are associated with distinct immunologic features. Kidney Int. 2002, nov;62(5):1764\u201375.","journal-title":"Kidney Int"},{"key":"4807_CR5","doi-asserted-by":"crossref","unstructured":"Delgado J, Voltz C, Stain M, Balkowiec-Iskra E, Mueller B, Wernsperger J, et al. The European medicines agency review of luspatercept for the treatment of adult patients with transfusion-dependent anemia caused by low-risk myelodysplastic syndromes with ring sideroblasts or beta-thalassemia. HemaSphere ao\u00fbt. 2021;5(8):e616.","DOI":"10.1097\/HS9.0000000000000616"},{"issue":"12","key":"4807_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis - a New look at an old entity. N Engl J Med. 2012, 22 mars 366(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"3","key":"4807_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41581-023-00778-x","volume":"20","author":"C Vlasschaert","year":"2024","unstructured":"Vlasschaert C, Lanktree MB, Rauh MJ, Kelly TN, Natarajan P. Clonal haematopoiesis, ageing and kidney disease. Nat Rev Nephrol. mars 2024;20(3):161\u201374.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"4807_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.ekir.2020.12.030","volume":"6","author":"N Schwotzer","year":"2021","unstructured":"Schwotzer N, Provot F, Ville S, Daniel L, Le Fur A, Kissling S, et al. Spectrum of kidney involvement in patients with myelodysplastic syndromes. Kidney Int Rep. mars 2021;6(3):746\u201354.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"4807_CR9","doi-asserted-by":"publisher","first-page":"6162","DOI":"10.1111\/jcmm.15243","volume":"24","author":"PA Martinez","year":"2020","unstructured":"Martinez PA, Li R, Ramanathan HN, Bhasin M, Pearsall RS, Kumar R, et al. Smad2\/3-pathway ligand trap luspatercept enhances erythroid differentiation in murine \u03b2-thalassaemia by increasing GATA-1 availability. J Cell Mol Med juin. 2020;24(11):6162\u201377.","journal-title":"J Cell Mol Med juin"},{"issue":"2","key":"4807_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1172\/JCI133678","volume":"130","author":"A Verma","year":"2020","unstructured":"Verma A, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, et al. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. J Clin Invest. 2020, 3 f\u00e9vr 130(2):582\u201389.","journal-title":"J Clin Invest"},{"issue":"7","key":"4807_CR11","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.3390\/jcm13071881","volume":"13","author":"AB Reiss","year":"2024","unstructured":"Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in chronic kidney disease: pathophysiology and therapeutic targets. J Clin Med. 2024, 25 mars 13(7):1881.","journal-title":"J Clin Med"},{"key":"4807_CR12","unstructured":"Tubule-derived INHBB promotes interstitial fibroblast activation and renal fibrosis. cit\u00e9 7 nov 2025]; Disponible sur: https:\/\/pathsocjournals.onlinelibrary.wiley.com\/doi\/10.1002\/path.5798."},{"issue":"3","key":"4807_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1681\/ASN.2015111230","volume":"28","author":"J Voelker","year":"2017","unstructured":"Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, et al. Anti-TGF-\u03b21 antibody therapy in patients with diabetic nephropathy. J Am Soc Nephrol. mars 2017;28(3):953.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4807_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41392-024-01764-w","volume":"9","author":"Z Deng","year":"2024","unstructured":"Deng Z, Fan T, Xiao C, Tian H, Zheng Y, Li C, et al. TGF-\u03b2 signaling in health, disease, and therapeutics. Signal Transduct Target Ther. 2024, 22 mars 9(1):61.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4807_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/path.5798","volume":"256","author":"Y Sun","year":"2022","unstructured":"Sun Y, Cai H, Ge J, Shao F, Huang Z, Ding Z, et al. Tubule-derived INHBB promotes interstitial fibroblast activation and renal fibrosis. J Pathol janv. 2022;256(1):25\u201337.","journal-title":"J Pathol janv"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04807-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04807-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04807-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T15:06:57Z","timestamp":1772723217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04807-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4807"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04807-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8189945\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This case report was conducted in accordance with the ethical principles of the Declaration of Helsinki. The study was approved by the Institutional Review Board of the GCS ELSAN #1 (approval number: 00012836). Written informed consent was obtained from the patient for publication of clinical data and images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient gave written informed consent for publication for his personal clinical data as well as for the publication of images from his renal biopsy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}